cancer

Fragment-based discovery: using smaller molecules to solve larger challenges

Thu Mar 24, 2016

ChemMedChem, 28 JAN 2016

Protease enzymes of the Kaposi’s sarcoma-associated herpesvirus (KSHV Pr) require two monomer proteins to combine into a dimer in order to activate. Dotted black box is the protein-protein interface targeted for disruption by Craik Lab researchers. (Colored balls represent amino acids—methionines—labeled to help determine if screened fragments inhibit dimerization.)

To discover new drugs and chemical probes, researchers have traditionally screened small molecules—small enough by weight to pass through cell membranes.

Abate honored by White House with Presidential Early Career Award

Fri Feb 19, 2016

Adam Abate, PhD

UCSF School of Pharmacy faculty member Adam Abate, PhD, has been named a recipient of the Presidential Early Career Award for Scientists and Engineers, the highest honor bestowed by the U.S. government on science and engineering professionals in the early stages of their independent research...

Altschuler and Wu develop new cell-screening approach to speed drug discovery

Wed Dec 16, 2015

Elisabeth Fall

Steven Altschuler, PhD, and Lani Wu, PhD

How do you discover new drugs against diseases such as cancer?

Kroetz leads new study of genetics of cancer drugs’ dose-limiting side effects

Mon Jul 27, 2015

Deanna Kroetz, PhD

Taxanes are a class of drugs widely used to treat a variety of cancers, including breast, ovarian, lung, gastric, and head and neck. But dosages are often limited by toxic side effects—most commonly damage to the body’s peripheral nerves, causing numbness, pain, and/or hyper-sensitivity—that can...

Dorie Apollonio, PhD, MPP

Wed Mar 6, 2013

Professor

My work considers the activities of industries implicated in the spread of non-communicable diseases, including tobacco, pharmaceuticals, cannabis, alcohol, and food. Some recent work has identified tobacco cessation strategies for vulnerable populations, sought to understand the scope of tobacco...

Francis Szoka, PhD

Wed Mar 6, 2013

Professor

I work with the dean as well as the vice dean of academic affairs to develop new avenues for incentivizing faculty success and retention.

During my research career, I applied biophysics, chemistry, and immunology to understand and devise better ways to deliver drugs, proteins, and nucleic acids to...

Study builds breast tissues to track how abnormal cells affect neighbors

Tue Oct 23, 2012

Zev Gartner, PhD

It can take just the flick of a genetic switch for breast cells to kick-start the normally well-regulated process of growth seen in puberty, pregnancy, or the menstrual cycle—or the mutation of that switch to initiate the unchecked proliferation of cancer.

Abate aided by QB3’s Startup in a Box program

Wed Sep 28, 2011

Adam Abate, PhD

Adam Abate, PhD, a faculty member in the UCSF Schools of Pharmacy and Medicine, Department of Bioengineering and Therapeutic Sciences, is a prime trial candidate for QB3’s Startup in a Box.

School of Pharmacy biotech symposium features case histories of future pharmaceuticals

Tue Aug 9, 2011

, UC Regents

The 2nd Annual Bay Area Biotechnology Symposium, presented by the UCSF School of Pharmacy’s Industry Outreach Program in coordination with the UCSF Postdoctoral Scholars Association at Mission Bay in late May 2011, fully lived up to its billing: “Pharmaceuticals of the Futur

UCSF technology used to trigger cell death becomes basis of company’s cancer therapy research and development

Thu Jul 8, 2010

James Wells, PhD

A technology developed in the laboratory of James Wells, PhD, chair of the Department of Pharmaceutical Chemistry, UCSF School of Pharmacy, will drive a new approach to cancer treatment that s

Topics and Expertise: cancer